[Moo Brief] MIRA Pharmaceuticals Surges 627% on Neurological Treatment Potential: A rising start-up in the making?

Moomoo CA joined discussion · 7 hours ago

[Moo Brief] MIRA Pharmaceuticals Surges 627% on Neurological Treatment Potential: A rising start-up in the making?

$MIRA Pharmaceuticals(MIRA.US)$ was hotly discussed yesterday , with its stock price surging by an impressive 627%. Between July 19 and July 22 market close, MIRA spiked from $0.69 to $5.01, with a price down to $3.9 after-hour at 7:59 PM EDT.

✏️ What happened?

$MIRA Pharmaceuticals(MIRA.US)$ made headlines on Monday by announcing that its novel oral ketamine analog, Ketamir-2, is being investigated as a potential treatment for neurological and neuropsychiatric disorders such as depression and post-traumatic stress disorder (PTSD). This news triggered a surge in the company's trading volume, with 156,802,800 shares traded on July 22 compared to 223,000 on July 16.

✏️ Who is MIRA?

$MIRA Pharmaceuticals(MIRA.US)$ is a preclinical-stage company based in the United States that was founded in 2020. The company's main focus is on developing two neuroscientific programs to address a broad range of neurologic and neuropsychiatric disorders. $MIRA Pharmaceuticals(MIRA.US)$'s main customers are expected to be healthcare providers, patients, and pharmaceutical companies.

As a preclinical-stage company, $MIRA Pharmaceuticals(MIRA.US)$ has not yet generated any revenue but has made progress in its research and development efforts, including the development of its novel oral marijuana, MIRA-55, and the licensing agreement for Ketamir-2. $MIRA Pharmaceuticals(MIRA.US)$'s ability to successfully bring these products to market and gain regulatory approval will be key factors in the company's future performance.

✏️ Why Ketamir-2 spurred market sentiment?

If $MIRA Pharmaceuticals(MIRA.US)$'s Ketamir is successfully applied, it will greatly improve treatment efficacy and safety, which are its competitive advantages. In addition, the large number of patients with neurological and neuropsychiatric disorders has aroused market expectations for MIRA.

Ketamir-2 ("Ketamir") is a novel analog of Ketamine with a unique structure and properties that is being investigated as a potential oral medication. It is aimed at providing ultra-rapid antidepressant effects for patients with treatment-resistant depression (TRD) and major depressive disorder with suicidal ideation (MDSI), offering new hope to those who have not responded to conventional treatments. Ketamir is characterized by its rapid antidepressant effects, superior oral bioavailability (estimated at 80%), and potential for at-home administration.

The sweeping AI wave seems to overshadow the pharmaceutical sector. As an investor, what do you think of $MIRA Pharmaceuticals(MIRA.US)$ that has the potential to provide treatment for depression? Would you consider investing in MIRA during this surge? Share your thoughts in the comments section!

Mooers' P/L

Some mooers definitely got mood up because of this wave, as you can see they profited from this surge:

@102446228 Read more>>